Active Ingredient History
Sodium oxybate is the sodium salt of gamma-hydroxybutyrate (GHB), an endogenous metabolite of gamma-aminobutyric acid (GABA) a major inhibitory neurotransmitter. Evidence suggests a role for GHB as a neuromodulator/neurotransmitter. Under endogenous conditions and concentrations, and depending on the cell group affected, GHB may increase or decrease neuronal activity by inhibiting the release of neurotransmitters that are co-localised with GHB. After exogenous administration, most of the observed behavioural effects appear to be mediated via the activity of GHB at GABA(B) receptors, as long as the concentration is sufficient to elicit binding, which does not happen at endogenous concentrations. Xyrem (sodium oxybate) oral solution is indicated for the treatment of cataplexy in narcolepsy and excessive daytime sleepiness (EDS) in narcolepsy. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Alcohol-Induced Disorders (Phase 4)
Alcoholism (Phase 4)
Alcohol Withdrawal Delirium (Phase 4)
Alzheimer Disease (Phase 4)
Anxiety Disorders (Phase 2)
Binge-Eating Disorder (Phase 2/Phase 3)
Brain Injuries, Traumatic (Early Phase 1)
Cataplexy (Phase 3)
Cluster Headache (Phase 3)
Disorders of Excessive Somnolence (Phase 3)
Dysphonia (Phase 2/Phase 3)
Essential Tremor (Phase 2)
Fatigue Syndrome, Chronic (Phase 4)
Fibromyalgia (Phase 3)
Healthy Volunteers (Phase 4)
Heart Failure, Systolic (Phase 2)
Idiopathic Hypersomnia (Phase 4)
Ketosis (Phase 2)
Narcolepsy ()
Opioid-Related Disorders (Phase 2)
Palliative Care (Phase 4)
Parkinson Disease (Phase 4)
Pediatrics (Phase 1/Phase 2)
REM Sleep Behavior Disorder (Phase 4)
Schizophrenia (Phase 2)
Sleep (Phase 4)
Sleep Apnea, Obstructive (Phase 4)
Sleep Disorders, Intrinsic (Phase 3)
Sleep Wake Disorders (Phase 3)
Stress Disorders, Post-Traumatic (Phase 2)
Substance Abuse, Oral (Phase 1)
Tremor (Phase 2/Phase 3)
Ventilation (Phase 2)
Ventilators, Mechanical (Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue